Literature DB >> 29568992

IgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT.

Xiao-Hui Zhang1,2,3, Xin Zhao4,5,6, Chen-Cong Wang4,5,6, Wei Han4,5,6, Huan Chen4,5,6, Yu-Hong Chen4,5,6, Feng-Rong Wang4,5,6, Jing-Zhi Wang4,5,6, Yuan-Yuan Zhang4,5,6, Xiao-Dong Mo4,5,6, Yao Chen4,5,6, Yu Wang4,5,6, Hai-Xia Fu4,5,6, Ying-Jun Chang4,5,6, Lan-Ping Xu4,5,6, Kai-Yan Liu4,5,6, Xiao-Jun Huang7,8,9.   

Abstract

Haploidentical hematopoietic stem cell transplant (haplo-HSCT) is an upfront and effective therapy for hematology patients, but it usually has many complications, such as neurological complications. As one of the neurological complications following haplo-HSCT, immune-mediated demyelinating diseases of the central nervous system (CNS) seriously affect a patient's quality of life. However, the incidence, risk factors, and pathogenesis of CNS demyelination are not very well understood. Thirty of the 1526 patients (1.96%) suffered from CNS demyelination. In univariate analysis, we found that blood-brain barrier (BBB) permeability and the CSF IgG synthesis index (IgG-Syn) were related to the occurrence of CNS demyelination (p < 0.05). In a multivariate analysis, the IgG-Syn (OR = 1.017, 95% CI 1.003-1.031, p = 0.019) and CSF anti-myelin oligodendrocyte glycoprotein antibody (MOG.Ab) (OR = 12.059, 95% CI 1.141-127.458, p = 0.038) were independently associated with the onset of CNS demyelination. We also studied the possible pathogenesis of CNS demyelination. Immune reconstitution (the cell proportions of CD19+ B cells, CD3+ T cells, and CD4+ T cells); the counts of leucocytes, lymphocytes, monocytes, and platelets; and the levels of immunoglobulins A, G, and M 30, 60, and 90 days after HSCT showed no significant differences between CNS demyelination and no demyelination (p > 0.05). The probabilities of overall survival showed no significant differences between patients with and without demyelination (p > 0.05). Only four deaths in 30 patients, but bringing projected survival to less than 20%.We imply that IgG-Syn and CSF MOG. Ab may be associated with the onset of CNS demyelination during 2 weeks of neurological symptoms in patients with brain or spinal cord MRI abnormality. Immune reconstitution may not be the pathogenesis of CNS demyelination.

Entities:  

Keywords:  Antibody; CNS demyelination; Haploidentical stem cell transplantation

Mesh:

Substances:

Year:  2018        PMID: 29568992     DOI: 10.1007/s00277-018-3299-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  4 in total

1.  Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation.

Authors:  Xuan Cai; Hai-Xia Fu; Xiao-Dong Mo; Yu Wang; Yuan-Yuan Zhang; Jin Wu; Wei Han; Fei-Fei Tang; Ruo-Yun Gui; Huan Chen; Yao Chen; Peng Zhao; Chen-Hua Yan; Jing-Zhi Wang; Yu-Hong Chen; Ying-Jun Chang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Bone Marrow Transplant       Date:  2020-04-24       Impact factor: 5.483

2.  Pure Red Cell Aplasia (PRCA) and Cerebellar Hypoplasia as Atypical Features of Polyglandular Autoimmune Syndrome Type I (APS-1): Two Sisters With the Same AIRE Mutation but Different Phenotypes.

Authors:  Matteo Chinello; Margherita Mauro; Gaetano Cantalupo; Rita Balter; Massimiliano De Bortoli; Virginia Vitale; Ada Zaccaron; Elisa Bonetti; Rossella Gaudino; Elena Fiorini; Simone Cesaro
Journal:  Front Pediatr       Date:  2019-02-26       Impact factor: 3.418

3.  Noninvasive tools based on immune biomarkers for the diagnosis of central nervous system graft-vs-host disease: Two case reports and a review of the literature.

Authors:  Hai-Rong Lyu; Xiao-Yuan He; Hong-Jun Hao; Wen-Yi Lu; Xin Jin; Yu-Jiao Zhao; Ming-Feng Zhao
Journal:  World J Clin Cases       Date:  2021-02-26       Impact factor: 1.337

Review 4.  Acute Graft-Versus-Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System.

Authors:  Janaki Manoja Vinnakota; Robert Zeiser
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.